The impact of the overactive bladder syndrome on sexual function: A preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial

American Journal of Obstetrics and Gynecology

Volumn 195, Issue 6, 2006, Pages 1730-1735

  Sand, Peter K ^a   Goldberg, Roger P ^a   Dmochowski, Roger R ^b   McIlwain, Marilyn ^d   Dahl, Naomi V ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Watson Laboratories Inc   (United States)

^d NONE

Author keywords

Overactive bladder; Quality of life; Sexual function; Transdermal oxybutynin; Urge urinary incontinence

Indexed keywords

OXYBUTYNIN;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTICHOLINERGIC SYNDROME; ARTICLE; BECK DEPRESSION INVENTORY; BLURRED VISION; CLINICAL TRIAL; COITUS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG EFFECT; FEMALE; HUMAN; KING HEALTH QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SEXUAL BEHAVIOR; SEXUAL FUNCTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; URGE INCONTINENCE; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; AGED; FEMALE; HUMANS; LIBIDO; MALE; MANDELIC ACIDS; MARRIAGE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUESTIONNAIRES; SEXUALITY; URINARY INCONTINENCE;

EID: 33751241464     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.08.013     Document Type: Article

References (22)

1. Coyne K.S., Payne C., Bhattacharyya S.K., Revicki D.A., Thompson C., Corey R., et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 7 (2004) 455-463
2. Temml C., Haidinger G., Schmidbauer J., Schatzl G., and Madersbacher S. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn 19 (2000) 259-271
3. Kim Y.H., Seo J.T., and Yoon H. The effect of overactive bladder syndrome on the sexual quality of life in Korean young and middle aged women. Int J Impotence Res 17 (2005) 158-163
4. Yip S.K., Chan A., Pang S., Leung P., Tang C., Shek D., et al. The impact of urodynamic stress incontinence and detrusor overactivity on marital relationship and sexual function. Am J Obstet Gynecol 188 (2003) 1244-1248
5. Gordon D., Groutz A., Sinai T., Wiezman A., Lessing J.B., David M.P., et al. Sexual function in women attending a urogynecology clinic. Int Urogyecol J Pelvic Floor Dysfunct 10 (1999) 325-328
6. Barber M.D., Visco A.G., Wyman J.F., Fantl J.A., and Bump R.C. Sexual function in women with urinary incontinence and pelvic organ prolapse. Obstet Gynecol 99 (2002) 281-289
7. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thuroff J., and Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87 (2001) 760-766
8. Stewart W.F., Van Rooyen J.B., Cundiff G.W., Abrams P., Herzog A.R., Corey R., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 (2003) 327-336
9. IMS National Prescription Audit. [database] (2003), IMS Health, Fairfield (Connecticut)
10. Zorn B.H., Montgomery H., Pieper K., Gray M., and Steers W.D. Urinary incontinence and depression. J Urol 162 (1999) 82-84
11. Ouslander J.G. Management of overactive bladder. N Engl J Med 350 (2004) 786-799
12. Moore K.H., Hay D.M., Imrie A.E., Watson A., and Goldstein M. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol 66 (1990) 479-485
13. Tapp A.J., Cardozo L.D., Versi E., and Cooper D. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 97 (1990) 521-526
14. Thuroff J.W., Bunke B., Ebner A., Faber P., de Geeter P., Hannappel J., et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145 (1991) 813-816
15. Buyse G., Waldeck K., Verpoorten C., Bjork H., Casaer P., and Andersson K.E. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 160 3 Pt 1 (1998) 892-896
16. Waldeck K., Larsson B., and Andersson K.E. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 157 (1997) 1093-1097
17. Davila G.W., Daugherty C.A., and Sanders S.W. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 166 (2001) 140-145
18. Dmochowski R.R., Davila G.W., Zinner N.R., Gittelman M.C., Saltzstein D.R., Lyttle S., et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 168 (2002) 580-586
19. Dmochowski R.R., Sand P.K., Zinner N.R., Gittelman M.C., Davila G.W., and Sanders S.W. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62 (2003) 237-242
20. Kelleher C.J., Cardozo L.D., Khullar V., and Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104 (1997) 1374-1379
21. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 561-571
22. Salonia A., Zanni G., Nappi R.E., Briganti A., Deho F., Fabbri F., et al. Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: results of a cross-sectional study. Eur Urol 45 (2004) 642-648